Form 4: Bionano CMO's Routine Tax Withholding on RSU Vesting

Bionano Genomics' Chief Medical Officer, Alka Chaubey, reported the withholding of 51 shares of common stock for tax obligations related to an RSU award vesting on September 11, 2025.

Summary

• Alka Chaubey, Chief Medical Officer of Bionano Genomics, Inc. (BNGO), reported a transaction involving the company's common stock.
• On September 11, 2025, 51 shares of common stock were withheld by the issuer.
• This withholding was to satisfy tax obligations upon the settlement of a Restricted Stock Unit (RSU) award.
• The RSU award was originally granted on September 11, 2023, and vested on September 11, 2025.
• The shares were withheld at a price of $4.06 per share.
• Following this transaction, Ms. Chaubey beneficially owns 662 shares of Bionano Genomics common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation (tax withholding on RSU vesting). It provides no new material information that would significantly alter the investment sentiment, thus it is neutral.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing represents a routine insider transaction, specifically a tax withholding event related to executive compensation. Such transactions are common across all industries when restricted stock units or similar equity awards vest, and do not typically reflect discretionary trading decisions by the insider.

Comparison to Industry Standards

• The withholding of shares for tax obligations upon the vesting of Restricted Stock Units (RSUs) is a standard practice in executive compensation across publicly traded companies, including those in the biotechnology and genomics sectors.
• This transaction aligns with typical corporate governance and compensation structures for executives receiving equity-based awards, similar to practices observed at companies like Illumina (ILMN) or Pacific Biosciences of California (PACB) when their executives' RSUs vest.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not indicate a change in management's view of the company's prospects.
• Employees: No direct impact beyond the reporting person.

Key Dates

Recommendation

The filing details a routine, non-discretionary transaction where shares were withheld for tax purposes upon RSU vesting. This type of insider transaction does not provide new material information to warrant a change in investment recommendation for Bionano Genomics. Investors should continue to evaluate the company based on its fundamental performance, strategic initiatives, and broader market conditions.

Keywords

Bionano Genomics, BNGO, Form 4, Insider Transaction, RSU, Stock Withholding, Alka Chaubey, Chief Medical Officer